Business news and discussion on TalkFuse.
Novartis raises blockbuster drug forecasts to $18 billion as it seeks to prove growth can last
Novartis has raised its forecast for sales from a blockbuster drug to $18 billion as it seeks to show investors that its growth can be sustained. The higher outlook comes amid questions about the Swiss drugmaker’s pipeline and spending after two recent clinical setbacks.
In September, a trial of cardiovascular drug pelacarsen failed to show improved outcomes. The next day, del-desiran failed in a late-stage trial, and Novartis shares fell nearly 11%, their biggest one-day drop since 1987. Chief executive Vas Narasimhan defended the company’s strategy, including its $12 billion acquisition of Avidity Biosciences, and cited a 275% total shareholder return over the past decade.
In short
- Novartis lifted its blockbuster drug sales forecast to $18 billion.
- Two experimental drugs recently failed in clinical trials.
- The chief executive defended the company’s acquisition strategy.
Steelman: both sides, in good faith
The strongest fair case each way — we don't pick a winner.
The case for
Raising the drug’s forecast to $18 billion gives investors a clearer sign of the company’s commercial potential and may show that growth can continue despite recent trial failures. Novartis can argue that taking calculated risks, including acquisitions and research spending, is necessary to replenish its pipeline and deliver long-term returns.
The case against
The higher forecast may not resolve concerns that Novartis’s future growth depends too heavily on a blockbuster while its pipeline has suffered setbacks. Investors can reasonably question whether costly acquisitions and spending will produce enough new medicines to sustain growth, particularly after the share-price fall and recent trial failures.
Explained simply
Novartis is a Swiss pharmaceutical company that develops and sells medicines. A blockbuster drug is one that brings in very large sales; companies often rely on such medicines to support revenue while they develop new treatments.
Investors also watch a company’s pipeline: the medicines it is testing and hopes to bring to market. Clinical trials assess whether a treatment is safe and effective, and failures can raise questions about future growth and the cost of research or acquisitions.
Vas Narasimhan is Novartis’s chief executive, responsible for leading the company and explaining its strategy to investors. The debate matters because long-term growth depends on balancing sales from established medicines with the uncertain prospects of new ones.